{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-089680","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.417978+00:00","generated_at":"2026-05-17T06:00:11.991999+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Allarity CEO to present at Biomarkers & Precision Medicine 2025 in London on Oct 1","bullets":["CEO Thomas Jensen invited to present at Oxford Global conference on October 1, 2025.","Presentation title: 'A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib'.","Jensen will also be interviewed by Oxford Global's editorial team for their online portal.","Jensen available for one-on-one meetings during the conference to discuss business development.","Allarity is a Phase 2 clinical-stage company developing dual PARP/WNT inhibitor stenoparib."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-089680","json":"https://secwatch.observer/filing/0001213900-25-089680.json","markdown":"https://secwatch.observer/filing/0001213900-25-089680.md","text":"https://secwatch.observer/filing/0001213900-25-089680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025089680/0001213900-25-089680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025089680/ea0258005-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:00:11.991999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}